Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Expenditures: 2013-2024

Historic Capital Expenditures for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $6.9 million.

  • ImmunityBio's Capital Expenditures fell 58.42% to $741,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 60.30%. This contributed to the annual value of $6.9 million for FY2024, which is 77.48% down from last year.
  • Per ImmunityBio's latest filing, its Capital Expenditures stood at $6.9 million for FY2024, which was down 77.48% from $30.6 million recorded in FY2023.
  • ImmunityBio's 5-year Capital Expenditures high stood at $78.2 million for FY2022, and its period low was $1.7 million during FY2020.
  • In the last 3 years, ImmunityBio's Capital Expenditures had a median value of $30.6 million in 2023 and averaged $38.5 million.
  • As far as peak fluctuations go, ImmunityBio's Capital Expenditures soared by 1,910.96% in 2021, and later tumbled by 77.48% in 2024.
  • Over the past 5 years, ImmunityBio's Capital Expenditures (Yearly) stood at $1.7 million in 2020, then soared by 1,910.96% to $33.6 million in 2021, then skyrocketed by 132.88% to $78.2 million in 2022, then plummeted by 60.87% to $30.6 million in 2023, then crashed by 77.48% to $6.9 million in 2024.